Chemopreventive effect of Minodronic acid hydrate for the patients treated with Aromatase inhibitor

Chemopreventive effect of Minodronic acid hydrate for the patients treated with Aromatase inhibitor - Chemopreventive effect of Minodronic acid hydrate for the patients treated with AI

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008567

Enrollment

Registered

2012-10-01

Start date

2012-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

medication unmedication

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: newly AI started breast cancer patients

Exclusion criteria

Exclusion criteria: Patients cannot use Minodronic acid hydrate

Design outcomes

Primary

Measure	Time frame
Efficacy	—

Secondary

Measure	Time frame
safety	—

Countries

Japan

Contacts

Public ContactMichi Miki

The University of Tokushima graduate school Department of Thoracic, Endocrine surgery and Oncology

surgery2@clin.med.tokushima-u.ac.jp088-633-7143

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026